Shares of Personalis (PSNL) soared by 20.63% in Monday's trading session, following a groundbreaking announcement regarding Medicare coverage for its key cancer detection product. The precision oncology company's stock price surge reflects strong investor optimism about the potential impact of this development on the company's future growth prospects.

Personalis revealed that its ultrasensitive NeXT Personal® test, designed for Minimal Residual Disease (MRD) detection in breast cancer patients, has received Medicare coverage. The Centers for Medicare & Medicaid Services Molecular Diagnostics Program approved coverage for post-treatment surveillance of cancer recurrence in patients with stage II and III breast cancer, effective retroactively from October 7, 2025. The NeXT Personal Dx Breast MRD Recurrence Monitoring Test will be reimbursed at $3,878 per test, while the NeXT Personal Single Plasma Test will be reimbursed at $1,158, available for up to six years post-treatment.

This Medicare coverage decision represents a significant milestone for Personalis, as it validates the clinical utility of their test and could pave the way for wider insurance coverage. The development is expected to substantially expand the accessibility of the test to a broader patient population, potentially driving increased adoption and revenue for the company. With breast cancer being one of the most common cancers worldwide, this coverage decision opens up a substantial market opportunity for Personalis, explaining the dramatic surge in its stock price as investors price in the potential for increased test volumes and revenue growth.